Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.

Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores

Abstracto

Targeted Therapies for Soft Tissue Sarcoma: New Horizons in Treatment

Rhys Moorish*

Soft tissue sarcoma (STS) encompasses a diverse group of rare and challenging malignancies originating from soft tissues. Historically, treatment options have been limited to surgery, radiation, and chemotherapy, often yielding suboptimal outcomes. However, the emergence of targeted therapies has revolutionized the landscape of STS treatment, offering new horizons and renewed hope for patients and clinicians alike. Targeted therapies represent a class of treatments designed to selectively target specific molecular abnormalities or pathways essential for tumor growth and survival. By honing in on these unique molecular targets, targeted therapies aim to achieve higher efficacy with reduced systemic toxicity compared to conventional chemotherapy.